Welcome to our dedicated page for Mink Therapeutics SEC filings (Ticker: INKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings rarely read like light bedtime material, and MiNK Therapeutics’ disclosures are no exception. Between pages of iNKT cell science, detailed R&D expense tables, and risk factors on manufacturing scale-up, investors can struggle to pinpoint what really moves the stock. That’s why our MiNK Therapeutics SEC filings page focuses on clarity first.
Stock Titan’s AI parses every 10-K annual report, 10-Q quarterly earnings report, and 8-K material event the moment MiNK submits them to EDGAR. Curious about a capital raise noted after market close? The “MiNK Therapeutics 8-K material events explained” summary highlights terms in plain English. Want to monitor leadership moves? Real-time alerts surface “MiNK Therapeutics Form 4 insider transactions,” letting you track executive stock purchases or sales as they post. Our engine even stitches together complex sections—so “understanding MiNK Therapeutics SEC documents with AI” becomes a five-minute task, not a weekend project.
Use the page to:
- Compare R&D spend trends across each MiNK Therapeutics quarterly earnings report 10-Q filing and see cash runway projections.
- Spot patterns in “MiNK Therapeutics insider trading Form 4 transactions” before key clinical milestones.
- Review the “MiNK Therapeutics proxy statement executive compensation” for option grants tied to trial success.
- Dive into “MiNK Therapeutics annual report 10-K simplified” sections on manufacturing scale and patent estate.
Whether you need a quick “MiNK Therapeutics earnings report filing analysis” or full document downloads, our comprehensive, real-time hub lets you move from data to decisions with confidence.
MiNK Therapeutics director reports new stock-based compensation. A company director received 1,263 restricted stock units (RSUs) of MiNK Therapeutics, Inc. common stock on 12/01/2025 at a value of $11.09 per share. These RSUs were granted in lieu of cash retainers for board and committee service and will vest one month after the grant date, at which point each RSU converts into one share of common stock. After this grant, the director beneficially owns 20,234 shares directly and 27,830 shares indirectly through an irrevocable trust established for the benefit of the director’s family.
MiNK Therapeutics (INKT) filed its Q3 2025 10‑Q, reporting continued losses and a going concern disclosure. Net loss was
The company raised liquidity via its at‑the‑market program, selling about 488,000 shares in Q3 for net proceeds of
Operating expenses reflected R&D of
MiNK Therapeutics filed a shelf registration to offer up to $150,000,000 of common stock, preferred stock, warrants, debt securities, and units. A related prospectus supplement establishes an at‑the‑market (ATM) program to sell up to $50,000,000 of common stock through B. Riley Securities, Inc.
Sales under the ATM are constrained by General Instruction I.B.6; based on a public float of $35,031,699 as of November 6, 2025, MiNK may currently sell up to $6,641,284 under the ATM. The Sales Agent’s compensation is 3.0% of gross proceeds. The company may sell directly, through agents, or via underwriters as described in the plan of distribution.
MiNK intends to use any net proceeds for working capital and general corporate purposes, including research and development, clinical programs, potential in‑licensing or acquisitions, collaborations, and capital expenditures.
MiNK Therapeutics insider Jennifer Buell amended a previously reported Form 4 to disclose that 5,351 shares of common stock were withheld to cover withholding taxes related to stock issued to her on 09/09/2025. The amended entry shows those withheld shares were disposed at a price of $15.36, leaving the reporting person with 36,492 shares beneficially owned. The amendment corrects an omission in the original Form 4 that did not include the tax-withheld shares in Table I.
MiNK Therapeutics insider grant: Chief Executive Officer Jennifer Buell received 18,229 shares of common stock and a stock option to purchase 50,000 shares on September 9, 2025, as part of her 2024 performance bonus. The issued shares were valued at $15.36 per share on the grant date and are fully vested on issuance but subject to a lockup that releases 100% on October 9, 2025. The option has an exercise price of $15.36, vests over three years (one-third at the first anniversary, then eight equal quarterly installments) and expires September 9, 2035. Following the transactions, Buell beneficially owned 41,913 shares and held 50,000 options.
MiNK Therapeutics director Robert Peter Kadlec was granted a stock option to buy 3,225 shares of common stock at an exercise price of $15.36 per share on 09/09/2025. The option is an award that vests in full on the one-year anniversary of the grant date if Mr. Kadlec remains on the board and expires on 09/09/2035. The Form 4 was filed for the reporting person identified at a New York address and signed by an attorney-in-fact on 09/11/2025. No cash proceeds were reported at the time of filing.
MiNK Therapeutics director Peter Behner was granted a stock option on 09/09/2025 to buy 3,225 shares of common stock at an exercise price of $15.36 per share. The option was reported on Form 4 filed 09/11/2025 and is exercisable through 09/09/2035. The option vests in full on the one-year anniversary of the grant date provided Mr. Behner continues to serve on the company's board through that date. Following the grant, Mr. Behner beneficially owns 3,225 shares via this option, held directly.
MiNK Therapeutics insider grant to director Brian Corvese: The filing reports a stock option grant awarding the Reporting Person the right to buy 3,225 shares of MiNK Therapeutics common stock at an exercise price of $15.36 per share. The transaction date is listed as 09/09/2025 and the option shows an expiration date of 09/09/2035 in the table. The form states the option "vests in full on the one-year anniversary of the date of grant" provided the reporting person continues to serve on the company’s board through that date. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/11/2025.
MiNK Therapeutics director Ulf Wiinberg received a grant of stock options on 09/09/2025 allowing purchase of 3,225 shares of common stock at an exercise price of $15.36 per share. The Form 4 shows the options were acquired (transaction code A) and the reporting person beneficially owns 3,225 shares following the transaction. The option term includes an expiration date shown as 09/09/2035 on the filing, and the filing discloses the option vests in full on the one‑year anniversary of the grant if the director continues to serve on the board through that date. The reporting person is identified as a director and the Form 4 was signed by an attorney‑in‑fact.
FAQ
What is the current stock price of Mink Therapeutics (INKT)?
What is the market cap of Mink Therapeutics (INKT)?
